Want Smarter Diabetes Monitoring in 2025? Here’s How to Choose the Best Blood Glucose Meter in Australia

Modern diabetes testing devices—including continuous glucose monitors (CGMs)—now provide real-time, continuous data and integration with apps and insulin pumps, offering greater convenience and features compared to traditional fingerprick meters. Some of the latest options include the Dexcom G7, Abbott FreeStyle Libre 2 Plus and Libre 3, Medtronic Simplera, and Eversense 365 CGM, with different choices for various diabetes management needs. This guide outlines current device options, features, eligibility and purchasing details, costs, and practical considerations for users in Australia in 2025.

Understanding the Main Diabetes Testing Methods

Modern blood sugar monitoring generally falls into two main categories:

Traditional Blood Glucose Meters

• Require fingerprick sampling
• Provide a single-point-in-time glucose reading
• Widely available without a prescription
• Typically lower initial cost
• Still used for CGM calibration or as a backup device

Note: Recent, detailed side-by-side comparisons of traditional meters for 2025 are limited. These meters fulfill their purpose but don’t offer the trend-tracking and alert functions of most CGMs.

Continuous Glucose Monitors (CGMs)

• Use a small sensor inserted under the skin, often on the back of the upper arm
• Deliver real-time, continuous glucose tracking (some provide readings every minute)
• Transmit data wirelessly to your phone, receiver, or compatible insulin pump
• Provide customizable high/low alerts and may offer predictive warnings
• May reduce or eliminate the need for frequent fingerpricks

Advanced CGMs and Blood Sugar Monitors Available in Australia (2025)

Here are some of the most current CGM options accessible in 2025:

Dexcom G7

• TGA approved; privately available since August 2024 in Australia
• Suitable for people with type 1 or type 2 diabetes
• Fast warm-up time (30 minutes); factory-calibrated (no fingerprick needed)
• Smaller sensor and less intrusive design compared to previous models
• Customizable alerts and predictive notifications
• Can integrate with selected insulin pumps and mobile apps
• Features designed to reduce waste and simplify application

Dexcom ONE+

• Developed for people with type 2 diabetes
• Compact sensor, quick setup, reduced waste
• Customizable alerts tailored around meal and medication timing
• Compatible with smartphone apps or a pocket receiver for those without smartphones
• Private market access; supply date for Australia not specified as of early 2025

Abbott FreeStyle Libre 2 Plus / Libre 3 / Libre 3 Plus

• FreeStyle Libre 2 Plus launch anticipated in Australia during 2025
  • Worn for up to 15 days (previous version: 14 days)
  • Approved for children as young as 2 years
  • Enhanced accuracy, integrated alerts, and compatible with certain insulin pumps
• FreeStyle Libre 3 (and 3 Plus):
  • Smaller sensors with 14- to 15-day wear options
  • Minute-by-minute automatic data transmission to apps
  • Increased Bluetooth range (up to 10 meters)
  • Data storage capacity for up to 14 days within the sensor
• These models are used by people with both type 1 and type 2 diabetes, including pediatric patients
• Provide app-based readings and in some cases integrate with selected pumps and wearable devices

Medtronic Simplera CGM

• TGA approved in January 2025; Australian availability forthcoming
• Disposable, all-in-one CGM system for adults 18 years and older
• Each sensor lasts up to six days with a 24-hour grace period, and supports overlapping use for smoother transitions
• Integrates with Medtronic pumps and In-Pen devices
• Requires a 2-hour warm-up time
• Offers app-based data access

Eversense 365 Implantable CGM

• Sensor implanted under the skin by a qualified health professional, usually in the upper arm
• Intended sensor life of up to 12 months, reducing replacement frequency
• Requires weekly fingerprick calibration after an initial period
• Transmitter offers vibration alerts directly to the user
• Waterproof and suitable for various daily activities
• Provides real-time data sharing with apps and healthcare providers
• Australian launch anticipated, but as of 2025 specific launch dates are not confirmed

Key Features to Consider

• Sensor lifespan: Varies from 6 days (Simplera) to 15 days (Libre 2 Plus, Libre 3 Plus), or up to 12 months (Eversense 365)
• Accuracy and alerts: Most devices offer real-time accuracy, factory or minimal calibration, and customizable alerts (including predictive options on certain models)
• App/ecosystem integration: Devices support apps for Android/iOS, facilitate sharing data with family or clinicians, and offer compatibility with some insulin pumps and automated insulin delivery systems
• Wearability: Most sensors are compact, water-resistant, and designed for comfortable arm placement (refer to manufacturer guidance for exceptions)
• Data storage/sharing: Devices generally feature automatic upload and sharing options, supporting collaborative care

Eligibility, Prescription, and Funding Information

• Traditional meters are available over the counter.
• CGMs require a prescription in Australia. Eligibility is often determined by the type of diabetes:
  • Most CGM subsidies through the NDSS in Australia are for people with type 1 diabetes
  • Some private health insurance policies may contribute to CGM costs
  • Subsidy options for type 2 diabetes are limited and subject to change, so check with NDSS, insurers, or your diabetes educator for the most current information
• Age restrictions apply: For example, Libre 3 Plus is suitable for children from 2 years; Simplera is for adults 18 and over.

Costs and Purchasing Considerations

• The latest CGMs have higher upfront costs compared to standard meters (e.g., Abbott FreeStyle Libre 2 sensors are approximately $100 each; costs may vary for new models)
• Subsidies are generally unavailable for type 2 diabetes unless you meet NDSS or insurance qualifications
• Ensure any device you consider is TGA registered. Be cautious of products marketed as “non-invasive” blood sugar testers without the appropriate regulatory approval

How to Avoid Scams and Non-Approved Devices

• There has been a rise in misleading advertisements for “non-invasive” blood glucose monitors within Australia
• Only consider devices registered with the TGA (Therapeutic Goods Administration) and be cautious of products making extraordinary claims or presenting unverified endorsements
• Consult a healthcare professional before making a purchase decision

Practical Suggestions for Choosing and Using a Diabetes Monitor

• Discuss options with your doctor or diabetes educator to align device choices with your health requirements and lifestyle
• Review device and app compatibility with your current technology, especially if you wish to share data with others or integrate with pumps
• Monitor product updates: New models and features are released regularly; confirm the latest availability, pricing, and subsidy status since policies and funding for type 2 diabetes may evolve during 2025
• Follow application guidance: Use device-specific instructions for sensor placement and avoid locations such as scars or prominent veins for optimal results

In 2025, Australians have a range of advanced blood glucose meters and diabetes monitors to support diabetes management. CGMs such as Dexcom G7, Abbott FreeStyle Libre 2 Plus and Libre 3, Medtronic Simplera, and Eversense 365 are among the options providing new features for accuracy, usability, and integration. Your selection should reflect your type of diabetes, feature preferences, eligibility for funding, and comfort with different devices. Prioritize devices approved by the TGA, seek guidance from healthcare professionals, and stay informed about new developments in diabetes care.

Sources

• What’s new in diabetes technology 2025 – Diabetes Qualified
• Best Continuous Glucose Monitors of 2025 – CNET

Disclaimer: All content, including text, graphics, images and information, contained on or available through this web site is for general information purposes only. The information and materials contained in these pages and the terms, conditions and descriptions that appear, are subject to change without notice.